Periodic screening with prostate-specific antigen testing reduced mortality from prostate cancer

Canfield, Steven E.
June 2009
ACP Journal Club;6/23/2009, Vol. 150 Issue 6, p3
Academic Journal
The article discusses whether constant screening for prostate cancer in men with prostate-specific antigen testing reduce mortality from prostate cancer. Randomized controlled trial was conducted on 1,62, 243 men aged 55 to 69 years in seven European countries. The intervention, outcomes and participants follow-up of the trial are discussed. It was concluded that periodic screening with prostate-specific antigen testing reduced mortality from prostate cancer in men aged 55 to 69 years.


Related Articles

  • Screening for Prostate Cancer Using Prostate-specific Antigen Alone as a First-line Checkup Parameter: Results of the Health Checkup System. Uchida, Katsunori; Takeshima, Hitoshi; Akaza, Hideyuki; Ono, Yukio // Japanese Journal of Clinical Oncology;Feb2000, Vol. 30 Issue 2 

    Discusses the results of primary prostrate cancer screening using serum prostrate-specific antigen (PSA) levels in a health checkup system in Japan. Cut-off value for PSA; Detection rates of prostrate cancer; Screening by digital rectal examination and transrectal ultrasonography; Usefulness of...

  • Annual screening for prostate cancer did not reduce mortality from prostate cancer. Canfield, Steven E. // ACP Journal Club;6/23/2009, Vol. 150 Issue 6, p2 

    The article discusses annual screening for prostate cancer in men in the age group of 55 to 74 years old. Randomized controlled trial was conducted on 76, 693 men in ten centers in the U.S. The intervention, outcomes and participants follow-up of the trial are discussed. It was concluded that...

  • Quality-of-Life Effects of Prostate-Specific Antigen Screening. Heijnsdijk, Eveline A.M.; Wever, Elisabeth M.; Auvinen, Anssi; Hugosson, Jonas; Ciatto, Stefano; Nelen, Vera; Kwiatkowski, Maciej; Villers, Arnauld; P�ez, Alvaro; Moss, Sue M.; Zappa, Marco; Tammela, Teuvo L.J.; M�kinen, Tuukka; Carlsson, Sigrid; Korfage, Ida J.; Essink-Bot, Marie-Louise; Otto, Suzie J.; Draisma, Gerrit; Bangma, Chris H.; Roobol, Monique J. // New England Journal of Medicine;8/16/2012, Vol. 367 Issue 7, p595 

    Background: After 11 years of follow-up, the European Randomized Study of Screening for Prostate Cancer (ERSPC) reported a 29% reduction in prostate-cancer mortality among men who underwent screening for prostate-specific antigen (PSA) levels. However, the extent to which harms to quality of...

  • Active Surveillance for Prostate Cancer. Thompson, Ian M.; Klotz, Laurence // JAMA: Journal of the American Medical Association;12/1/2010, Vol. 304 Issue 21, p2411 

    The authors reflect on the active surveillance approach in preventing, diagnosing and treating prostate cancer. They note that active surveillance with treatment reserved for evidence of rapid prostate-specific antigen (PSA) progression or increase in tumor volume or grade is associated with...

  • Prostate Cancer Mortality in Areas With High and Low Prostate Cancer Incidence. Stattin, Pär; Carlssoän, Sigrid; Holmström, Benny; Vickers, Andrew; Hugosson, Jonas; Lilja, Hans; Jonsson, Håkan // JNCI: Journal of the National Cancer Institute;Mar2014, Vol. 106 Issue 3, p1 

    Background The effect of prostate-specific antigen (PSA) screening on prostate cancer mortality remains debated, despite evidence from randomized trials. We investigated the association between prostate cancer incidence, reflecting uptake of PSA testing, and prostate cancer mortality. Methods...

  • Prostate cancer: to screen or not to screen? Schroder, Fritz H. // BMJ: British Medical Journal (International Edition);2/13/93, Vol. 306 Issue 6875, p407 

    Examines the diagnosis of prostate cancer. Percentage of mortality caused by the disease; Treatment of cancer; Identification of cancers discovered at necropsy.

  • Earlier, less frequent PSA screens discover PCa. Guttman, Cheryl // Urology Times;Nov2000, Vol. 28 Issue 11, p1 

    Reports that the measurement of prostate specific antigen (PSA) at an earlier age is an effective diagnostic tool for prostate cancer. Comparison of the results of a computer model using screening and diagnostic resource use with the numbers of prevented cancer deaths associated with different...

  • Alternative screening methods may reduce mortality in prostate cancer.  // Hem/Onc Today;4/25/2013, Vol. 14 Issue 8, p11 

    The article discusses the results of a study which showed that mortality was reduced by prostate cancer screening methods that increase the threshold for biopsy referral for older men and lessen screening among those with low prostate-specific antigen (PSA).

  • Comparative Efficiency of Prostate-Specific Antigen Screening Strategies for Prostate Cancer Detection. Ross, Kevin S.; Carter, H. Ballentine; Pearson, Jay D.; Guess, Harry A. // JAMA: Journal of the American Medical Association;9/20/2000, Vol. 284 Issue 11, p1399 

    Presents a study to compare prostate cancer mortality, prostate-specific antigen (PSA) testing rates and biopsy rates, using prostate-specific antigen (PSA) screening strategies. Context; Design; Results; Conclusion that the efficacy of prostate-specific antigen (PSA) screening is unproved.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics